Clinical development of anticancer agents from natural products

STEM CELLS

Volumn 12, Issue 1, 1994, Pages 30-43

  Parkinson, David R ^a   Arbuck, Susan G ^a   Moore, Timothy ^a   Pluda, James M ^a   Christian, Michaele C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Bryostatin; Camptothecin; Chemotherapy; Docetaxel; Fumagillin; Mitotic spindle; Paclitaxel; Taxanes; Topoisomerase I

Indexed keywords

ANTHRACYCLINE; BRYOSTATIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CISPLATIN; DNA TOPOISOMERASE; DOCETAXEL; FLUOROURACIL; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; IRINOTECAN; LACTONE; MAYTANSINE; PACLITAXEL; PROTEIN KINASE; TAXANE DERIVATIVE; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BREAST CANCER; CANCER RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG PROGRAM; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LUNG CANCER; LYMPHOMA; MELANOMA; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; FATTY ACIDS, UNSATURATED; LACTONES; PACLITAXEL; PLANTS, MEDICINAL;

ANIMALIA;

EID: 0027982781     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.5530120108     Document Type: Article

References (93)

1. Plant antitumor agents. VI The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia
2. Structure‐activity study of cytotoxicity and microtubule assembly in vitro by Taxol and related taxanes
3. Antitumor alkaloids
4. Cytologic evidence that Taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison
5. Promotion of microtubule assembly in vitro by Taxol
6. Taxol stabilizes microtubules in mouse fibroblast cells
7. Mechanism of action of Taxol
8. Anaphylaxis: consequence of yew (Taxus) needle ingestion
9. Phase I trial of taxotere: 5 day schedule
10. A phase II trial of Taxol and granulocyte colony stimulating factor (G‐CSF) in patients with adenocarcinoma of the pancreas
11. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
12. Phase II trial of Taxol as second‐line therapy for ovarian carcinoma: a Gynecologic Oncology Group study
13. Phase II study and long‐term follow‐up of patients treated with Taxol for advanced ovarian cancer
14. Taxol dose intensification (D.I.) in patients with recurrent ovarian cancer
15. Paclitaxel for platinum‐refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103
16. Phase II trial of Taxol: an active drug in the treatment of metastatic breast cancer
17. Activity of Taxol with recombinant granulocyte colony stimulating factor (GCSF) as first chemotherapy (C) of patients (PTS) with metastatic breast cancer (MBC)
18. A phase II study of Taxol (NSC 125973) in patients (pts) with non‐small cell lung cancer (NSCLC)
19. Phase II study of Taxol in patients with stage IV non‐small cell lung cancer (NSCLC): the Eastern Cooperative Oncology Group (ECOG) results
20. Taxol: the first of the taxanes, an important new class of antitumor agents
21. Taxol (NSC 235973) in advanced hormone refractory prostate cancer: an ECOG phase II trial
22. Phase II trial of Taxol in patients (Pts) with renal cell carcinoma
23. A phase II trial of Taxol in metastatic melanoma
24. Phase II study of Taxol in patients (Pts) with malignant melanoma
25. A new and practical approach to the synthesis of Taxol and Taxol analogs: the pinene path
26. Studies with RP56976 (Taxotere): a semisynthetic analog of Taxol
27. Experimental antitumor activity of Taxotere (RP56976, NSC 628503), a Taxol analog
28. Taxol in relapsed ovarian cancer: high vs low dose and short vs long infusion: a European‐Canadian study coordinated by the NCI Canada Clinical Trials Group
29. The activity of Taxol in human bladder tumor cell lines
30. Current dosage and schedule issues in the development of paclitaxel (TAXOL)
31. Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin‐sensitive and resistant human ovarian carcinoma cell lines
32. Taxol sensitizes human astrocytoma cells to radiation
33. P‐glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines
34. Plant antitumor agents. 1 The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
35. Studies on therapeutic effectiveness of drugs with tumor weight and survival time indices of Walker 256 carcinosarcoma
36. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin
37. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogs
38. Preliminary pharmacologic and clinical evaluation of camptothecin sodium
39. Phase I clinical trial of weekly and daily oral treatment with camptothecin sodium
40. Phase II study of camptothecin (NSC‐100880)
41. Treatment of malignant melanoma with camptothecin (NSC‐100880)
42. Effects of camptothecin on RNA synthesis in leukemia L1210 cells
43. Effects of chemotherapeutic agents on RNA synthesis in L1210 cells
44. Effects of camptothecin on the breakage and repair of DNA during the cell cycle
45. The effects of camptothecin on mammalian DNA
46. Camptothecin induced protein‐linked DNA breaks via mammalian DNA topoisomerase I
47. Biochemical basis for the interactions of type I and type II topoisomerases with DNA
48. Synthesis and biological activity in the camptothecin series
49. CPT‐11 converting enzyme from rat serum: purification and properties
50. Intracellular roles of SN‐38, a metabolite of the camptothecin derivative CPT‐11, in the antitumor effect of CPT‐11
51. The current status of camptothecin analogs as antitumor agents
52. Therapeutic efficacy of the topoisomerase‐I inhibitor 7‐ethyl‐10‐(4‐[1 ‐piperidino]‐1‐piperidino)‐carbonyloxy‐campto thecin against human tumor xenografts: lack of cross‐resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9‐dimethylaminomethyl‐10‐hydroxycamptothecin
53. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK &F 104864) given as an intravenous bolus every 21 days
54. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor
55. Phase I/pharmacokinetic trial of topotecan on a weekly 24‐hour infusion schedule
56. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory of relapsed acute leukemia
57. Topotecan 21 day continuous infusion‐excellent tolerance of a novel schedule
58. DNA topoisomerase I‐targeted chemotherapy of human colon cancer in xenografts
59. Total synthesis of the novel water soluble camptothecin analog GI 147211C, a potent topoisomerase I inhibitor
60. Synthetic analogs of fumagillin that inhibit angiogenesis and suppress tumour growth
61. An antiphage agent isolated from Aspergillus sp
62. Fumagillin (H‐3), a new antibiotic with amebicidal properties
63. The treatment of amebiasis with fumagillin
64. Suppression of tumor metastasis by angiogenesis inhibition
65. Potent anti‐angiogenic action of AGM‐1470: comparison to the fumagillin parent
66. Analysis of experimental antiangiogenic therapy
67. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O‐(chloroacetyl‐carbamoyl) fumagillol TNP‐470: AGM‐1470
68. Inhibitory effect of angiogenesis inhibitor TNP‐470 on tumor growth and metastasis of human cell lines in vitro and in vivo
69. Inhibition of angiogenesis and growth of human nerve‐sheath tumors by AGM‐1470
70. Angiogenesis inhibitor TNP‐470 (AGM‐1470) potently inhibits the tumor growth of hormone‐independent human breast and prostate carcinoma cell lines
71. Isolation and structure of bryostatin 1
72. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity
73. Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma
74. Bryostatin 1, a unique biologic response modifier: anti‐leukemic activity in vitro
75. Induction of apoptosis and potentiation of the action of 1‐beta‐D‐arabinofuranosylcytosine (ara‐C) in human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C (PKC)
76. Varied differentiation responses of human leukemias to bryostatin 1
77. Bryostatin induces changes in protein kinase C and activity without altering c‐myc gene expression in human promyelocytic leukemia cells (HL‐60)
78. Towards selective pharmacological modulation of protein kinase C—opportunities for the development of novel antineoplastic agents
79. Successful treatment of murine melanoma with bryostatin 1
80. Activation and growth of murine tumor‐specific T‐cells which have in vivo activity with bryostatin 1
81. Sensitization of human cervical carcinoma cells to cis‐diamminedichloroplatinum by bryostatin 1
82. The National Cancer Institute: cancer drug discovery and development program